During the third quarter, Centene paid $229 million to transition from using the RxAdvance platform, according to an SEC filing.

Join The Ecosystem

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}